American Well Corporation

NYSE:AMWL

Medical - Healthcare Information Services

Healthcare
$11.03 +2.82%

+$0.24 today

Market cap
$171.77M
Beta
1.70
P/E (TTM)
-1.6
EPS (TTM)
-$5.30
52W Low $3.71High $9.96

Volume 0.06M

Average 0.07M

AMWL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

American Well CorporationNYSE: AMWL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $12.38M fell 44.0% year over year, behind the -22.5% change in trailing-twelve-month research & development. Sequentially, it fell 11.2% from the prior quarter. Over 3 fiscal years it compounded at -19.3% a year.

Context

  • Research & development amounted to 29.2% of revenue in FY2025, down 4.6 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -44.0% toward the trailing-twelve-month pace of -22.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.38M-11.2% QoQ
Last fiscal yearDec 2025
$72.86M-15.3% YoY
LTMMar 2026
$63.14M-22.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.0%——
1 year-15.3%——
3-year CAGR-19.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
72.86M USD
Year-over-year change
-15.3%
4-year CAGR
-9.1%

Research & Development vs competitors

How AMWL compares with its peers on the latest reported figures

  • AMWL's LTM Mar 2026 research & development of $63.14M is the 4th highest of the 9 companies compared; the peer median is $54.54M.
  • Its year-over-year change of -22.5% is the 7th highest of 9, against a peer median of -5.1%.
  • Research & development amounts to 26.6% of revenue for AMWL, versus a peer median of 538.3%.
AMWL Competitors Peer median
Research & Development for AMWL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMUXImmunic, Inc.LTM Mar 2026$86.08M +3.9%+4.8%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$70.7M -6.3%+29.5%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$66.71M -38.5%-7.9%—
AMWLAmerican Well CorporationLTM Mar 2026$63.14M -22.5%-19.3%26.6%
ATYRaTyr Pharma, Inc.LTM Mar 2026$55.72M +5.5%+12.0%29327.4%
DTILPrecision BioSciences, Inc.LTM Mar 2026$53.36M -10.8%+5.5%118.4%
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M -55.0%-0.4%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$37.7M -3.9%—958.2%
EUDAEUDA Health Holdings LimitedLTM Jun 2026$1.53K +525.4%-75.6%0.0%
Peer median (excluding AMWL) $54.54M-5.1%+4.8%538.3%

Competitors are the stored peer set for AMWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue252.79M277.19M259.05M254.36M249.33M
Cost of Revenue148.47M160.42M164.29M155.41M116.47M
Gross Profit104.32M116.77M94.76M98.95M132.86M
Gross Margin41.3%42.1%36.6%38.9%53.3%
Research & Development106.59M138.49M105.83M86.07M72.86M
Selling, General & Admin160.78M227.98M213.11M197.45M131.31M
Operating Expenses283.46M392.62M786.9M316.49M238.13M
Depreciation & Amortization16.09M26.17M31.51M32.98M33.96M
EBITDA(166.07M)(245.84M)(224.15M)(176.91M)(60.57M)
EBITDA Margin-65.7%-88.7%-86.5%-69.6%-24.3%
Operating Income(179.15M)(275.85M)(692.14M)(217.53M)(105.27M)
Operating Margin-70.9%-99.5%-267.2%-85.5%-42.2%
Interest Income120K6.12M19.42M10.76M3.8M
Interest Expense00000
Other Income / Expenses(3.01M)3.85M16.83M7.65M10.74M
Income Before Tax(182.16M)(272.01M)(675.31M)(209.89M)(94.53M)
Pre-Tax Margin-72.1%-98.1%-260.7%-82.5%-37.9%
Income Tax Expense(5.38M)64K3.86M2.75M434K
Net Income(176.33M)(270.43M)(675.16M)(208.14M)(95.7M)
Net Margin-69.8%-97.6%-260.6%-81.8%-38.4%
EPS (Basic)(13.88)(19.68)(47.50)(13.88)(5.96)
EPS (Diluted)(13.88)(19.68)(47.50)(13.88)(5.96)
Weighted Avg Shares12.7M13.71M14.21M15M16.05M
Weighted Avg Shares (Diluted)12.7M13.71M14.21M15M16.05M

American Well Corporation

NYSE:AMWL

Intrinsic Alpha fair value

Locked

Current Price

$11.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.